Ronald van Vollenhoven
0000-0001-6438-8663
Publication & Citation Trends
Publications
0 total
PREDICTION OF RESPONSE TO RITUXIMAB IN SLE USING A VALIDATED TWO-SCORE SYSTEM FOR INTERFERON
Cited by 1
Semantic Scholar
Suppression of Serum Interferon‐γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus OA
Cited by 6
Semantic Scholar
USING A VALIDATED
Cited by 0
Semantic Scholar
AB0850 CUTANEOUS LUPUS ERYTHEMATOSUS DISEASE AREA & SEVERITY INDEX (CLASI) DEMONSTRATES THRESHOLDS FOR DETECTION OF TREATMENT RESPONSE IN A PHASE 2, PLACEBO-CONTROLLED TRIAL OF USTEKINUMAB IN SLE OA
Cited by 0
Semantic Scholar
OP0161 ASSOCIATION OF BASELINE CYTOTOXIC GENE EXPRESSION WITH USTEKINUMAB RESPONSE IN SYSTEMIC LUPUS ERYTHEMATOSUS OA
Cited by 2
Semantic Scholar
O9 Reduction of interferon-γ and elevated baseline cytotoxic gene expression in the blood associate with ustekinumab response in SLE OA
Cited by 0
Semantic Scholar
201 Ustekinumab targets a novel mechanism of action to treat patients with systemic lupus erythematosus OA
Cited by 0
Semantic Scholar
OP0278 BIOMARKER PROFILING REVEALS NOVEL MECHANISTIC INSIGHTS INTO USTEKINUMAB THERAPEUTIC RESPONSES IN SYSTEMIC LUPUS ERYTHEMATOSUS OA
Cited by 2
Semantic Scholar
Research Topics
Systemic Lupus Erythematosus Research
(506)
Rheumatoid Arthritis Research and Therapies
(480)
Monoclonal and Polyclonal Antibodies Research
(221)
Chronic Lymphocytic Leukemia Research
(173)
Autoimmune and Inflammatory Disorders Research
(158)
Affiliations
Linköping University
Leiden University
American College of Rheumatology
Mount Sinai Hospital
Dalhousie University